This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
PowerBlock v. iFit (Fed. Cir., August 11, 2025) 2024-1177
Condensed IP
12 minutes
2 months ago
PowerBlock v. iFit (Fed. Cir., August 11, 2025) 2024-1177
This is an opinion from the United States Court of Appeals for the Federal Circuit regarding the case of PowerBlock Holdings, Inc. v. iFit, Inc. The core issue revolves around the patent eligibility of PowerBlock's U.S. Patent No. 7,578,771, which pertains to selectorized dumbbells with automated weight adjustment. The Court of Appeals reversed the district court's decision, which had found most claims of the patent to be ineligible under 35 U.S.C. § 101 because they were deemed "abstract ide...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
